Phaseline

Targets › PROT

PROT (Sodium-dependent proline transporter): drug programs, companies and trials

2 programs from 2 companies in 29 trials: 17 Phase 2, 7 Phase 3, 4 Phase 4, 1 Phase 1; Infectious disease; next expected readout Dec 2026.

Brain specific sodium (and chloride)-dependent proline transporter. Terminates the action of proline by its high affinity sodium-dependent reuptake into presynaptic terminals (Probable). (UniProt, Q99884)

Open in Phaseline: the race on PROT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Instituto Mexicano del Seguro SocialDarunavir
Human immunodeficiency virus type 1 protease inhibitor
PROT, CYP3A4, POLR2APhase 4HIV InfectionDec 2026
Gilead SciencesLenacapavir
Structural capsid protein inhibitor
CA, CPSF6, GAG, PROT, UNKNOWN, CAPSIDPhase 3Pre-Exposure Prophylaxis of HIV Infection; HIV Pre-exposure Prophylaxis; HIV Infections; HIV-1-infection …Mar 2027

Conditions

HIV-1-infection (10) Pre-Exposure Prophylaxis of HIV Infection (7) HIV-1 Infection (3) HIV Infection (2) HIV Pre-exposure Prophylaxis (2) HIV Infections (1) HIV-1-Infection (1) HIV (1) HIV Prevention (1) Human Immunodeficiency Virus (1)

Modalities

small molecule (1), mixed (1)

Companies

Instituto Mexicano del Seguro Social (1) Gilead Sciences (1)

Related targets

CYP3A4 (1) POLR2A (1) CA (1) CPSF6 (1) GAG (1) UNKNOWN (1) CAPSID (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.